And the beat goes on: formulary restriction, generic substitution, prior authorization, drug utilization, and now therapeutic interchange
Burkhart, C.G.
Journal of Drugs in Dermatology Jdd 3(1): 11
2004
ISSN/ISBN: 1545-9616 PMID: 14964740 Document Number: 568361
Document emailed within 1 workday
Related Documents
Mahoney, C.D. 1992: Issues in formulary management: therapeutic interchange. The value, cost, and quality of therapeutic interchange Hospital Formulary 27 Suppl. 2: 2-3Brust, M.; Hawkins, C.F.; Grayson, D. 1990: Physicians' attitudes toward generic drug substitution by pharmacists Texas Medicine 86(3): 45-49
Kaojarern, S.; Pattanaprateep, O. 2012: The effect of introducing inpatient mandatory generic drug substitution at Ramathobodi Hospital Journal of the Medical Association of Thailand 95(4): 519-525
Wang, Y.R.; Pauly, M.V. 2005: Prescription drug formulary design, preferred-product marketshare, and formulary noncompliance: a study of proton-pump inhibitors Managed Care Interface 18(8): 39-45
Bendix, J. 2014: The prior authorization predicament Medical Economics 91(13): 29-30 32 34-5
Hauser, D. 2015: MMA goes head on against medication prior authorization Minnesota Medicine 98(3): 26-27
Wood, D. 2015: Prior authorization reform: We are just getting started Minnesota Medicine 98(7): 36
Terry, K. 2007: Prior authorization made easier Medical Economics 84(20): 34 38 40
Artherholt, W.G. 1988: Therapeutic drug substitution Iowa Medicine: Journal of the Iowa Medical Society 78(10): 485-486
Dowell, J.S.; Snadden, D.; Dunbar, J.A. 1995: Changing to generic formulary: how one fundholding practice reduced prescribing costs Bmj 310(6978): 505-508
1989: Screening criteria for prior authorization for ten surgical procedures Rhode Island Medical Journal 72(2): 67-70
Boissonnas, A. 1994: How to treat a patient with AIDS and drug dependence unwilling and/or unable to withdraw? Give substitution drugs at the hospital? Should substitution be continued after discharge? Is substitution a useful adjuvant to programs designed to prevent opportunistic diseases?] opportunisticinfections? Annales de Medecine Interne 145 Suppl. 3: 54-55
Zellmer, W.A. 1988: Therapeutic interchange American Journal of Hospital Pharmacy 45(3): 535
Kubica, A.J.; Bowman, G.K. 1977: Guidelines for determining generic substitution American Journal of Hospital Pharmacy 34(7): 677
Chalchat, B. 1996: Generic drugs and substitution rights: Pandora's box? Annales Pharmaceutiques Francaises 54(6): 284-286
Schuler, S. 1992: Critical comments on the contribution by N. Scherbaum and N. Gaspar. Substitution with methadone as a therapeutic approach in the treatment of drug dependent patients Der Nervenarzt 63(7): 450-451
Flood, J.; Mihalik, C.; Fleming, R.R.; Strober, B.E.; Zucker, D.R.; Burgoyne, D.S. 2007: The use of therapeutic interchange for biologic therapies Managed Care 16(1): 51-62
Lawrenz, C.A.; Cole, P.; Theodorou, A.; Cook, R.L.; Bermann, L. 1991: Therapeutic interchange of ampicillin-sulbactam for cefoxitin American Journal of Hospital Pharmacy 48(10): 2150-2154
Straughan, J.; Largier, D. 2002: Particular care should be taken by pharmacists and physicians before introducing generic substitution is supported South African Medical Journal 92(11): 838
Weissenfeld, J.; Stock, S.; Lüngen, M.; Gerber, A. 2010: The nocebo effect: a reason for patients' non-adherence to generic substitution? Die Pharmazie 65(7): 451-456